Teva Pharmaceutical Industries (TEVA) Change in Cash (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Change in Cash across 10 years of filings, most recently posting $185.0 million for Q1 2026.

• Quarterly Change in Cash rose 111.54% year-over-year to $185.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 258.08% YoY) and the FY2025 annual result came in at $256.0 million, up 245.95% from the prior year.
• Change in Cash declined to $185.0 million in Q1 2026, from $1.4 billion in the prior quarter.
• Over five years, Change in Cash peaked at $1.4 billion in Q4 2025 and troughed at -$1.6 billion in Q1 2025.
• A 5-year average of $90.8 million and a median of $52.0 million in 2022 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2023 — Change in Cash sank 1365.38% — and 2025, when it surged 7616.67%.
• Tracing TEVA's Change in Cash over 5 years: stood at $576.0 million in 2022, then jumped by 69.62% to $977.0 million in 2023, then slumped by 101.84% to -$18.0 million in 2024, then jumped by 7616.67% to $1.4 billion in 2025, then slumped by 86.33% to $185.0 million in 2026.
• Business Quant data shows TEVA's Change in Cash at $185.0 million in Q1 2026, $1.4 billion in Q4 2025, and $42.0 million in Q3 2025.